Cetuximab: Cetuximab is an EGFR inhibitor, a fully humanized mAB, with FDA-approval for patients with K-Ras wild-type, EGFR-expressing colorectal cancer, metastatic colorectal cancer and advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. This evidence concerns the gene EGFR and squamous cell carcinoma.